Advertisement

Autografting in Chronic Myeloid Leukemia

  • Eduardo Olavarria
Part of the Hematologic Malignancies book series (HEMATOLOGIC)

Abstract

Autografting was first attempted for patients with chronic myeloid leukemia (CML) in transformation in order to restore a second chronic phase (CP). The principal rationale for autografting in CP resides on the reduction of the tumor burden and the number of leukemic cells at risk of developing blastic transformation, and the possibility of eradicating already mutated cells. In a European Group for Blood and Marrow Transplantation (EBMT) survey, patients with CML in CP, undergoing autologous stem cell transplantation (SCT) for the first time, had an overall survival of 65% at 5 years from transplant with more than 50% of all patients remaining in CP. The main point made by this retrospective study was that in patients refractory to interferon alpha (IFN), 70% achieved a cytogenetic response post autografting, which was complete or major in 31%. Since the advent of imatinib, autografting in CML has experienced a substantial decline. Theoretically, there are several possible ways of using autologous SCT in combination with imatinib: (1) to reverse resistance to imatinib; (2) to eliminate a Ph-positive clone bearing a BCR-ABL kinase domain mutation; and (3) to reduce the level of residual disease after a cytogenetic response to imatinib in patients in whom Ph-negative cells had been harvested.

Keywords

Chronic Myeloid Leukemia Chronic Myelogenous Leukemia Autologous Stem Cell Transplantation Peripheral Blood Stem Cell Chronic Myeloid Leukemia Patient 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Apperley JF, Boque C, Carella A et al (2004) Autografting in chronic myeloid leukaemia: a meta-analysis of six randomised trials. Bone Marrow Transplant 33:S28Google Scholar
  2. Archimbaud E, Michallet M, Philip I et al (1997) Granulocyte colony-stimulating factor given in addition to interferon-alpha to mobilize peripheral blood stem cells for autologous transplantation in chronic myeloid leukaemia. Br J Haematol 99:678–684PubMedCrossRefGoogle Scholar
  3. Bhatia R, Forman SJ (1998) Autologous transplantation for the treatment of chronic myelogenous leukemia. Hematol Oncol Clin North Am 12(1):151–172PubMedCrossRefGoogle Scholar
  4. Boiron JM, Cahn JY, Meloni G et al (1999) Chronic myeloid leukaemia in first chronic phase not responding to a-interferon: outcome and prognostic factors after autologous transplantation. Bone Marrow Transplant 24:259–264PubMedCrossRefGoogle Scholar
  5. Bouzgarrou R, Reiffers J (1991) Cellules souches circulantes et LMC: modalités de prélèvement, congélation, décongélation, reconstitution hématologique après greffe. Presented at the Réunion du groupe Hémobiologie du FAG, 22 Octobre 1991Google Scholar
  6. Brito-Babapulle F, Bowcock SJ, Marcus RE et al (1989) Autografting for patients with chronic myeloid leukaemia in chronic phase: peripheral blood stem cells may have a finite capacity for maintaining haematopoiesis. Br J Haematol 73:76–81PubMedGoogle Scholar
  7. Buckner CD, Stewart P, Clift RA et al (1978) Treatment of blastic transformation of chronic granulocytic leukaemia by chemotherapy, total body irradiation and infusion of cryopreserved autologous marrow. Exp Hematol 6:96–109PubMedGoogle Scholar
  8. Butturini A, Keating A, Goldman J, Gale RP (1990) Autotransplants in chronic myelogenous leukaemia: strategies and results. Lancet 335:1255–1258PubMedCrossRefGoogle Scholar
  9. Carella AM, Frassoni F (1996) ICE, mini-ICE or high-dose hydroxyurea to mobilize Philadelphia [Ph]-negative PBPC in chronic myelogenous leukaemia. Br J Haematol 95:213–214PubMedCrossRefGoogle Scholar
  10. Carella AM, Frassoni F, Negrin RS (1995) Autografting in chronic myelogenous leukemia: new questions. Leukemia 9:365–369PubMedGoogle Scholar
  11. Carella AM, Lerma E, Corsetti MT et al (1999) Autografting with Philadelphia chromosome negative mobilized hematopoietic progenitor cells in chronic myelogenous leukemia. Blood 83:1534–1539Google Scholar
  12. Carlo-Stella C, Regazzi E, Andrizzi C et al (1997) Use of granulocyte-macrophage colony-stimulating factor (GM-CSF) in combination with hydroxyurea as post-transplant therapy in chronic myelogenous leukemia patients autografted with unmanipulated hematopoietic cells. Haematologica 82(3):291–296PubMedGoogle Scholar
  13. Coulombel L, Kalousek DK, Eaves CJ, Gupta CM, Eaves AC (1983) Long-term marrow culture reveals chromosomally normal hematopoietic progenitor cells in patients with Philadelphia chromosome positive chronic myelogenous leukemia. N Engl J Med 308:1493–1498PubMedCrossRefGoogle Scholar
  14. Daley GQ (1996) Rationalizing autotransplant strategies for chronic myeloid leukemia. Leuk Lymphoma 21(5–6):353–358PubMedGoogle Scholar
  15. Deisseroth AB, Zu Z, Claxton D et al (1994) Genetic marking shows that Ph+ cells present in autologous transplants of chronic myelogenous leukemia (CML) contribute to relapse after autologous bone marrow in CML. Blood 83:3068–3076PubMedGoogle Scholar
  16. Drummond MW, Marin D, Clark RE et al (2003) Mobilization of Ph chromosome-negative peripheral blood stem cells in chronic myeloid leukaemia patients with imatinib mesylate-induced complete cytogenetic remission. Br J Haematol 123:479–483PubMedCrossRefGoogle Scholar
  17. Enright H, McGlave P (1998) Bone marrow transplantation for chronic myelogenous leukemia. Curr Opin Oncol 10:100–107PubMedGoogle Scholar
  18. Gladstone DE, Bedi A, Miller CB et al (1999) Philadelphia chromosome-negative engraftment after autologous transplantation with granulocyte-macrophage colony-stimulating factor for chronic myeloid leukemia. Biol Blood Marrow Transplant 5(6): 394–399PubMedCrossRefGoogle Scholar
  19. Goldman JM (1997) Treatment of chronic myeloid leukaemia: some topical questions. Baillieres Clin Haematol 10(2):405–421PubMedGoogle Scholar
  20. Goldman JM, Th’ng KH, Park DS et al (1978) Collection, cryopreservation and subsequent viability of haemopoietic stem cells intended for treatment of chronic granulocytic leukemia in blast-cell transformation. Br J Haematol 40:185–195PubMedGoogle Scholar
  21. Goldman JM, Catovsky D, Hows J, Spiers ASD, Galton DAG (1979) Cryopreserved peripheral blood cells functioning as autografts in patients with chronic granulocytic leukaemia in transformation. Br Med J 1:1310–1313PubMedCrossRefGoogle Scholar
  22. Haines ME, Goldman JM, Worsley et al (1984) Chemotherapy and autografting for chronic granulocytic leukaemia in transformation: probable prolongation of survival in some patients. Br J Haematol 58:711–721PubMedGoogle Scholar
  23. Hehlmann R, Hochhaus A, Berger U, Reiter A (2000) Current trends in the management of chronic myelogenous leukemia. Ann Hematol 79:345–54PubMedCrossRefGoogle Scholar
  24. Hoyle C, Gray R, Goldman J (1994) Autografting for patients with CML in chronic phase: an update. Br J Haematol 86:76–81PubMedGoogle Scholar
  25. Jazwieck B, Mahon FX, Pigneux A et al (1995) 5-Fluorouracil-resistant CD34+ cell population from peripheral blood of chronic myelogenous leukemia patients contains BCR-ABL negative progenitor cells. Exp Hematol 23:1509–1514Google Scholar
  26. Kantarjian HM, Smith TL, O’Brien S et al (1995) Prolonged survival in chronic myelogenous leukemia following cytogenetic response to alpha interferon therapy. Ann Intern Med 122:254–261PubMedGoogle Scholar
  27. Khouri IF, Kantarjian H, Talpaz M et al (1996) Results with high-dose chemotherapy and unpurged autologous stem cell transplantation in 73 patients with chronic myelogenous leukaemia: the MD Anderson experience. Bone Marrow Transplant 17:775–779PubMedGoogle Scholar
  28. Kirk JA, Reems JA, Roecklein BA et al (1995) Benign marrow progenitors are enriched in CD34+/HLA — DRlo population but not in the CD34+/38lo population in chronic myeloid leukemia: an analysis using interphase fluorescence in situ hybridization. Blood 86:737–743PubMedGoogle Scholar
  29. Kreuzer KA, Kluhs C, Baskaynak G et al (2004) Filgrastim-induced stem cell mobilization in chronic myeloid leukaemia patients during imatinib therapy: safety, feasibility and evidence for an efficient in vivo purging. Br J Haematol 124(2):195–199PubMedCrossRefGoogle Scholar
  30. Mahon FX, Faberes C, Pueyo S et al (1998) Response at three months is a good predictive factor for newly diagnosed chronic myeloid leukemia patients treated by recombinant alpha interferon. Blood 92:4059–4065PubMedGoogle Scholar
  31. McGlave PB, De Fabritiis P, Deisseroth J et al (1994) Autologous transplants for chronic myelogenous leukaemia: results from eight transplant groups. Lancet 343:1486–1488PubMedCrossRefGoogle Scholar
  32. Meloni G, De Fabritiis P, Alimena F et al (1990) Autologous bone marrow transplantation or peripheral blood stem cell transplantation for patients with chronic myelogenous leukaemia in chronic phase. Bone Marrow Transplant 4(Suppl. 4):92–94Google Scholar
  33. Meloni G, Russo D, Baccarani M et al (1999) A prospective study of alpha-interferon and autologous bone marrow transplantation in chronic myeloid leukemia. The Italian Co-operative Study Group on Chronic Myeloid Leukemia. Haematologica 84:707–715PubMedGoogle Scholar
  34. Miller JS (1998) Innovative therapy for chronic myelogenous leukemia. Hematol Oncol Clin North Am 12(1):173–206PubMedCrossRefGoogle Scholar
  35. O’Brien SG (1997) Autografting for chronic myeloid leukaemia. Baillieres Clin Haematol 10(2):369–388PubMedCrossRefGoogle Scholar
  36. Olavarria E, Kanfer E, Szydlo R et al (2000a) High-dose busulphan alone as cytoreduction before allogeneic or autologous stem cell transplantation for chronic myeloid leukaemia: a single-centre experience. Br J Haematol 108:769–777PubMedCrossRefGoogle Scholar
  37. Olavarria E, Parker S, Craddock C et al (2000b) Collection of Ph-negative progenitor cells from interferon responsive patients with chronic myeloid leukemia: effect of granulocyte-colony-stimulating factor mobilization. Haematologica 85(6):647–652PubMedGoogle Scholar
  38. Olavarria E, Reiffers J, Boque C et al (2002) The post-transplant cytogenetic response to interferon is a major determinant of survival after autologous stem cell transplantation for chronic myeloid leukaemia in chronic phase. Br J Haematol 118:762–770PubMedCrossRefGoogle Scholar
  39. Perseghin P, Gambacorti-Passerini C, Tornaghi L et al (2005) Peripheral blood progenitor cell collection in chronic myeloid leukemia patients with complete cytogenetic response after treatment with imatinib mesylate. Transfusion 45(7):1214–1220PubMedCrossRefGoogle Scholar
  40. Petzer AL, Eaves CJ, Lansdorp PM et al (1996) Characterization of primitive subpopulation of normal and leukemic cells in the blood of patients with newly diagnosed as well as established chronic myeloid leukemia. Blood 88:2162–2171PubMedGoogle Scholar
  41. Pigneux A, Faberes C, Boiron JM et al (1999) Autologous stem cell transplantation in chronic myeloid leukemia: a single center experience. Bone Marrow Transplant 24:265–270PubMedCrossRefGoogle Scholar
  42. Rainey MG, Harrison P, Hows JM et al (1996) Spontaneous graft-versus-host disease following autologous peripheral blood progenitor cell transplantation in chronic myeloid leukaemia. Bone Marrow Transplant 17(6):1077–1079PubMedGoogle Scholar
  43. Reiffers J (1985) Autologous transplantation in chronic myelogenous leukemia. Blood Transfusion Immunohematol 28:509–520CrossRefGoogle Scholar
  44. Reiffers J, Trouette R, Marit G et al (1991) Autologous blood stem cell transplantation for chronic granulocytic leukaemia in transformation: a report of 47 cases. Br J Haematol 77:339–345PubMedGoogle Scholar
  45. Reiffers J, Cahn JY, Montastruc M et al (1993) Peripheral blood stem cell transplantation followed by recombinant alpha interferon for chronic myelogenous leukemia in chronic phase: preliminary results. Stem Cells 11:23–24PubMedCrossRefGoogle Scholar
  46. Reiffers J, Goldman J, Meloni G, Cahn JY, Gratwohl A on behalf of the Chronic Leukaemia Working Party of the EBMT (1994) Autologous stem cell transplantation in chronic myelogenous leukaemia: a retrospective analysis of the European Group for Bone Marrow Transplant. Bone Marrow Transplant 14:407–410PubMedGoogle Scholar
  47. Reiffers J, Mahon FX, Boiron JM et al (1996a) Autografting in chronic myeloid leukaemia: an overview. Leukemia 10:385–388PubMedGoogle Scholar
  48. Reiffers J, Goldman JM, Meloni G, Cahn JY, Apperley J (1996b) Autologous stem cell transplantation (Auto-SCT) for chronic myeloid leukemia (CML) in chronic phase: a report of the European Blood and Marrow Transplant (EBMT) Group. 22nd Annual Meeting of the EBMT, Vienna (Austria) Bone Marrow Transplant 17(Suppl.1), S3, abstract no. 56Google Scholar
  49. Reiffers J, Taylor K, Gluckman E et al (1998) Collection of Ph-negative progenitor cells with granulocyte-colony stimulating factor in patients with chronic myeloid leukaemia who respond to recombinant alpha-interferon. Br J Haematol 102:639–646PubMedCrossRefGoogle Scholar
  50. Rowe JM, Rapoport AP, Ryan DH et al (1999) Treatment of chronic myelogenous leukemia with autologous bone marrow transplantation followed by roquinimex. Bone Marrow Transplant 24(10): 1057–1063PubMedCrossRefGoogle Scholar
  51. Russo D, Martinelli G, Montefusco V et al (1999) Collection of Ph-negative progenitor cells from Ph+ CML patients in complete cytogenetic remission after long-term interferon-alpha therapy. Haematologica 84(10):953–955PubMedGoogle Scholar
  52. Silver RT, Woolf SH, Helhmann R et al (1999) An evidence-based analysis of the effect of busulfan, hydroxyurea, interferon, and allogeneic bone marrow transplantation in treating the chronic phase of chronic myeloid leukemia: developed for the American Society of Hematology. Blood 94:1517–1536PubMedGoogle Scholar
  53. Simonsson B, Oberg G, Bjoreman M et al (2005) Intensive treatment and stem cell transplantation in chronic myelogenous leukemia: long-term follow-up. Acta Haematol 113(3):155–162PubMedCrossRefGoogle Scholar
  54. Spencer A, Granter N, Fagan K et al (1998) Collection and analysis of peripheral blood mononuclear cells during haemopoietic recovery following PBSCT for CML: autografting as an in vivo purging manoeuvre? Bone Marrow Transplant 21(1):101–103PubMedCrossRefGoogle Scholar
  55. The Italian Cooperative Study Group on Chronic Myeloid Leukaemia (1993) Karyotype conversion by interferon as preparative treatment for autologous BMT in Ph positive CML. Leuk Lymphoma 11(Suppl 1):277–280Google Scholar
  56. The Italian Cooperative Study Group on chronic myeloid leukemia (1994) Interferon alpha — 2a as compared with conventional chemotherapy for the treatment of Chronic Myeloid Leukemia. N Engl J Med 330:820–825CrossRefGoogle Scholar

Copyright information

© Springer Berlin Heidelberg 2007

Authors and Affiliations

  • Eduardo Olavarria
    • 1
  1. 1.Catherine Lewis Centre, Haematology DepartmentHammersmith HospitalLondonUK

Personalised recommendations